Immune checkpoint inhibitors against PD-1, PD-L1 and CTLA-4 have altered the treatment
paradigm for various types of cancers in the past decade. However, they offer clinical …

The functional status of CD4+ T cells is a critical determinant of antitumor immunity.
Polyfunctional CD4+ T cells possess the ability to concomitantly produce multiple Th1-type …

Solid tumors are complex masses with a local microenvironment, or stroma, that supports
tumor growth and progression. Among the diverse tumor-supporting stromal cells is a …

Combination therapy with α-CTLA-4 and α-PD-1 has shown significant clinical responses in
different types of cancer. However, the underlying mechanisms remain elusive. Here …

Tumor-specific CD8+ T cells are key effectors of antitumor immunity but are often rendered
dysfunctional in the tumor microenvironment. Immune checkpoint blockade can restore …

The presence of activated intratumoral T cells correlates clinically with better prognosis in
patients with cancer. Although tumor vaccines can increase the number of tumor-specific …

Although immune checkpoint inhibitors (ICIs) are established as effective cancer therapies,
overcoming therapeutic resistance remains a critical challenge. Here we identify interleukin …

Background Although accumulated evidence provides a strong scientific premise for using
immune profiles to predict survival in patients with cancer, a universal immune profile across …

A single intratumoral injection of IL-12 and GM-CSF-loaded slow-release microspheres
induces T cell-dependent eradication of established primary and metastatic tumors in a …

Mouse CD8+ T cells conditioned with interleukin (IL)-12 ex vivo mediate the potent
regression of established melanoma when transferred into lymphodepleted mice. However …